Stockreport

Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of th...

Can-Fite Biopharma Ltd Sponsored ADR (Israel)  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com
PDF Interim analysis data is expected Q4 2020Can Fite possesses US patent protecting the anti-viral effects of its two drug candidates and is exploring collaboration to test [Read more]